Ranjan Perera,
Associate Professor, Scientific Director Genomics and Bioinformatics,
Sanford Burnham Medical Research Institute
Dr. Perera is an Associate Professor and Scientific Director, Analytical Genomics and Bioinformatics at Sanford-Burnham Medical Research Institute. His research focuses on the molecular mechanisms by which non-coding RNAs (miRNAs and lncRNAs) might affect melanoma and prostate cancer development in humans. Prostate cancer and metastatic melanoma are both difficult cancers to detect early, and once detected late they are nearly always impossible to cure, causing mortality within three years despite surgery and conventional therapies. To find effective treatment it is imperative to understand the biology of these aggressive cancers. Prior to joining Sanford-Burnham Medical Research Institute, Dr. Perera held positions at several major biotech and pharmaceutical companies, including ISIS Pharmaceuticals and Life Technologies Corporation. He received his Ph.D. in molecular genetics from Moscow State University, Russia and University of Gent, Belgium. Dr. Perera completed his postdoctoral studies in gene targeting and DNA recombination at Massachusetts Institute of Technology (MIT).
The Long Noncoding RNA SPRIGHTLY (SPRY4-IT1): A New Player in Different Diseases
Monday, 13 November 2017 at 11:30
Add to Calendar ▼2017-11-13 11:30:002017-11-13 12:30:00Europe/LondonThe Long Noncoding RNA SPRIGHTLY (SPRY4-IT1): A New Player in Different DiseasesThe RNA Summit: Research, Diagnostics and Therapeutics in Boston, USABoston, USASELECTBIOenquiries@selectbiosciences.com
Long noncoding RNAs (lncRNAs) were once dismissed as non-functional genomic noise. There is now compelling evidence that lncRNAs play critical roles in human pathophysiology. However, the molecular mechanisms by which the vast majority of lncRNAs regulate their target genes, and proteins remain unclear. The goal of this project is to characterize the molecular mechanisms and regulatory functions of a critical lncRNA, SPRIGHTLY, which is known to participate in human diseases and cancer development. We and others have previously reported that SPRIGHTLY (formally called SPRY4-IT1) is transcribed from the first intron of the SPRY4 gene and is downregulated in normal human melanocytes but highly upregulated in human melanomas and other cancers. By determining SPRIGHTLY’s 3D structure by SHAPE-seq and using this structure to probe interacting RNA molecules by pull-down experiments, we have identified six cancer-related pre-mRNAs that preferentially bind to SPRIGHTLY. Hemizygous knockout (using CRISPR) of SPRIGHTLY in melanoma cells significantly decreases SPRIGHTLY lncRNA levels and simultaneously the levels of its interacting pre-mRNA molecules, decreases anchorage-independent growth, and reduces in vivo tumor growth in mouse xenografts. This is the first demonstration of a lncRNA’s 3D coordinating role in cancer-related gene expression, but how SPRIGHTLY regulates target pre-mRNA expression from genetically unlinked loci at the genomic and epigenomic levels is unknown. We will discuss the therapeutic and biomarker potential of SPRIGHTLY, and our research should provide novel and general insights into how lncRNAs regulate cellular states through their interactions with target molecules in human cancers.
Add to Calendar ▼2017-11-13 00:00:002017-11-14 00:00:00Europe/LondonThe RNA Summit: Research, Diagnostics and TherapeuticsThe RNA Summit: Research, Diagnostics and Therapeutics in Boston, USABoston, USASELECTBIOenquiries@selectbiosciences.com
Add to Calendar ▼2017-11-13 11:30:002017-11-13 12:30:00Europe/LondonThe Long Noncoding RNA SPRIGHTLY (SPRY4-IT1): A New Player in Different DiseasesThe RNA Summit: Research, Diagnostics and Therapeutics in Boston, USABoston, USASELECTBIOenquiries@selectbiosciences.com
